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ABSTRACT
Objectives: People who inject drugs (PWID) are at
high risk for acquiring hepatitis C virus (HCV), but many
are unaware of their infection. HCV dried blood spot
(DBS) testing increases case-finding in addiction
services and prisons. We determine the cost-
effectiveness of increasing HCV case-finding among
PWID by offering DBS testing in specialist addiction
services or prisons as compared to using venepuncture.
Design: Cost-utility analysis using a dynamic HCV
transmission model among PWID, including: disease
progression, diagnosis, treatment, injecting status,
incarceration and addition services contact.
Setting: UK.
Intervention: DBS testing in specialist addiction
services or prisons. Intervention impact was determined
by a meta-analysis of primary data.
Primary and secondary outcome measures: Costs
(in UK £, £1=US$1.60) and utilities (quality-adjusted life
years, QALYs) were attached to each state and the
incremental cost effectiveness ratio (ICER) determined.
Multivariate uncertainty and one-way sensitivity
analyses were performed.
Results: For a £20 000 per QALY gained
willingness-to-pay threshold, DBS testing in addiction
services is cost-effective (ICER of £14 600 per QALY
gained). Under the base-case assumption of no
continuity of treatment/care when exiting/entering
prison, DBS testing in prisons is not cost-effective
(ICER of £59 400 per QALY gained). Results are robust
to changes in HCV prevalence; increasing PWID
treatment rates to those for ex-PWID considerably
reduces ICER (£4500 and £30 000 per QALY gained for
addiction services and prison, respectively). If
continuity of care is >40%, the prison DBS ICER falls
below £20 000 per QALY gained.
Conclusions: Despite low PWID treatment rates,
increasing case-finding can be cost-effective in
specialist addiction services, and in prisons if continuity
of treatment/care is ensured.
INTRODUCTION
In developed countries, the hepatitis C virus
(HCV) is spread primarily through injecting
drug use, with over 90% of new infections
among people who inject drugs (PWID).1
However, diagnosis rates are low, with only
half of the infected PWID in the USA and
the UK diagnosed.2
The majority of HCV testing performed in
the USA and the UK is through venepunc-
ture, which is available in virtually all
prisons,3 and addiction services (structured
programmes providing pharmacological or
non-pharmacological drug treatment in the
community) either on site or by referral.
However, testing opportunities among PWID
may still be limited. This is because venous
access can be poor and specialist staff (who
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may not be available at all potential testing sites) are
required to take blood, which if only available in hos-
pital phlebotomy services can increase stigma.4
Dried blood spot (DBS) testing is non-invasive and can
be performed by clinical and non-clinical staff. Two UK
studies5 6 showed that offering DBS testing within special-
ist addiction services and prisons led to a threefold to
sixfold increase in HCV testing, and a recent systematic
review identified DBS as the best available targeted inter-
vention for increasing HCV case-finding among PWID.7
Hence, DBS testing could be an important component of
any strategy attempting to scale up treatment provision
for PWID, for both care and prevention.8
We perform a cost-utility analysis of introducing DBS
testing among current and former PWID in specialist
addiction services and prisons in the UK.5 Unlike previ-
ous economic evaluations of HCV testing in these set-
tings,9 10 we incorporate a dynamic mathematical model
to capture the potential prevention benefits of treat-
ment, which can substantially increase the cost-
effectiveness of HCV treatment for PWID.11 A dynamic
model accounts for the individual and population bene-
fits of treatment, as well as the dynamic nature of incar-
ceration, especially among PWID. Our model is the first
to explore the importance of continuity of care between
prison and the community.
METHODS
Mathematical model
An existing dynamic, deterministic model of HCV trans-
mission, progression and HCV treatment was adapted to
project the impact of introducing DBS testing in prisons
and addiction services.11 See online supplementary
appendix for details and model schematics. Briefly, the
model stratifies by: injecting state (never PWID/PWID/
ex-PWID); incarceration status (never/currently/for-
merly); contact with addiction services (in contact/not
in contact); age ((15–19), (20–24), (25–29), (30–54),
(55–64), (65–74), (75+)); HCV infection and disease
progression (never infected, spontaneously cleared, mild
HCV, moderate HCV, compensated cirrhosis, decompen-
sated cirrhosis, hepatocellular carcinoma, liver trans-
plant, post-transplant). HCV disease stages are further
subdivided into undiagnosed or diagnosed, where those
who are diagnosed can either be lost to follow-up, in
referral (early/late), on antiviral treatment, sustained
viral response (SVR) or non-SVR.
All PWID can acquire and transmit HCV, but impri-
soned PWID only transmit HCV to other prisoners. We
define ex-PWID as those who have permanently ceased
injecting, and assume no ongoing transmission from
non/ex-PWID. An individual’s risk of acquiring HCV is
proportional to the setting-specific HCV prevalence
(prison/community). The model assumes a background
rate of HCV testing for all PWID and ex-PWID in the
community/prison, and in addiction services for PWID.
No UK data exist regarding continuity of care (treat-
ment or referral) on prison entry/exit, but experts
described difficulty in ensuring continuity on release
(Eamonn O’Moore(Offender Health, UK Department
of Health), Iain Brew(HMP Leeds) personal communica-
tion). Therefore, in our base case, we assume that those
in treatment or referral become lost to follow-up upon
entering/exiting prison, but can be retested/retreated.
Model fitting and base-case projections
For the probabilistic uncertainty analysis, 1000 param-
eter sets were sampled from each parameter uncertainty
distribution in table 1 and online supplementary
appendix tables 1 and 2. For the parameter set, the
model was calibrated to UK epidemiological data on
incarceration, injecting drug use, HCV prevalence and
diagnosis. This was achieved through a multistep param-
eter sampling and model calibration process, utilising
simplified models where possible to reduce computa-
tional time and to verify the full model predictions
against simplified models. For details on the model cali-
bration (including schematics and equations) and initial-
isation (see online supplementary appendix).
After calibration, for each of the 1000 parameter sets,
the model was run with and without the intervention
(‘intervention’ and ‘baseline’, respectively). We model
an intervention of offering DBS testing in prison, com-
pared to a baseline of current testing with venepuncture
only. Additionally, we evaluate an intervention of offer-
ing DBS in specialist addiction services, compared to a
baseline of current testing with venepuncture. The eco-
nomic analysis was performed from a UK National
Health Service perspective. Costs (in 2011 GBP, £1=US
$1.55) and health utilities (in QALYs) were attached to
each model compartment. Costs and QALYs were dis-
counted at 3.5% per annum as per the National
Institute for Health and Clinical Excellence guidelines,
with a 100-year time horizon (to accrue individual and
population benefits). The mean incremental cost-
effectiveness ratio (ICER) was calculated and cost-
effectiveness determined using the UK willingness-to-pay
(WTP) threshold, estimated between £20 000 and
£30 000 per QALY gained.12 The cost-effectiveness
acceptability curves were constructed and univariate sen-
sitivity analyses undertaken. Analysis of covariance
(ANCOVA) methods were used to summarise the pro-
portion of the variability in the incremental costs and
QALYs explained by the uncertainty in input
parameters.13
Parameters
All parameters can be found in table 1 and the online
supplementary appendix tables 1–4.
Health state utilities
Uninfected utility values were taken from the UK popu-
lation norms for non-PWID, and a large cross-sectional
study of injectors in Scotland14 for current PWID. We
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assumed equal utilities for ex-PWID and non-PWID.10
Utilities for the HCV disease and treatment stages came
from the UK HCV trials and economic evaluations15–17
and were used for ex-PWID. To derive PWID HCV util-
ities, non-PWID HCV utilities were rescaled by multiply-
ing by the ratio of the uninfected PWID utility to the
uninfected ex-PWID utility for the youngest age group.
All states included disutilities with age.
No disutility was associated with testing in the base
case. However, some evidence suggests that PWID may
experience a disutility after positive HCV diagnosis.14 18
We explored the impact of a disutility (0.09,14 see online
supplementary appendix) on diagnosis, which was fully
regained with treatment SVR.
Health state and testing costs
Healthcare costs for HCV disease stages, antiviral treat-
ment (pegylated interferon-α and ribavirin, pegIFN
+RBV) and testing were taken from the UK economic
analyses.15 16 19 20 Data on the yield (proportion tests
Ab+) and prevalence in each setting were used to calcu-
late the number of non-PWID tested for each PWID/
ex-PWID (see online supplementary appendix). Costs
were inflated to 2011 GBP using the Health and
Community Hospital Service pay and prices index.21
Additional PWID treatment delivery costs were
applied.11 We assumed that undiagnosed individuals
would not incur HCV-related healthcare costs unless
progressing to decompensated disease.9
HCV disease progression parameters
Transition rates between disease stages were taken from
the UK economic evaluations.15–17 Although estimates
were not PWID-specific, a recent meta-analysis suggests
little evidence for differences in progression between
PWID and non-PWID.22
HCV prevalence
PWID HCV chronic prevalence was estimated from the
HCV antibody prevalence among PWID in England
(45% (41% to 49%, 95%CI)23). As one-quarter of acute
infections spontaneously clear, 24 we assume three-
quarters of those who are ever exposed (antibody posi-
tive) are chronically infected, resulting in 35% chronic
infection among PWID.
Incarceration duration
Incarceration duration for non-PWID and ex-PWID was
age-stratified, with a mean of 8 months.25 However,
PWID have shorter durations in custody than
Table 1 Intervention parameters
Mean value Distribution Units References
Intervention effect (proportional change in testing rate)
Addiction services 3.6 (2.3–5.8) Lognormal
(μ=1.285, σ=0.239)
–
5
Prison 2.6 (0.2–34.9) Lognormal
(μ=0.968, σ=1.317)
–
5
Intervention costs (addiction services)
Organisation/coordination of training* 2005.71 Per health board †
Training session‡ 135 Per training session †
Attendees time§ 1620 Per training session †
Travel reimbursement for training leader¶ 90.86 Per training session †
Total cost per addiction services training 3851.57 Per training session †
Mean number tested 40.3 Per addiction service** 5
Total intervention cost per test 95.57 Uniform±50% Per test
Intervention costs (prison)
Organisation/coordination of training†† 7020 Per prison †
Training session‡ 135 Per prison †
Attendees time‡‡ 405 Per prison †
Travel reimbursement for training leader§§ 127.20 Per prison †
Total cost per prison training 7687.20 Per prison †
Mean number tested per prison 116 Per prison 5
Total intervention cost per test 66.27 Uniform±50% Per test
All cost estimates assume a staff-nurse cost per hour of £36 (median estimate for band 5 general practice nurse21).
*1 Nurse 2 days/week for 6 months for seven health boards. One training session per health board.
†Noel Craine, personal communication.
‡1 Nurse, half day.
§12 Nurses, half day.
¶1200 miles (£0.53 per mile) for travel to seven health boards.
**Assumed 1 addiction service per health board.
††1 Nurse full time for five prisons (1 training session per prison).
‡‡3 Nurses per prison, half day.
§§1200 miles (£0.53 per mile) for five prisons.
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non-PWID.25–27 We used a 4-month PWID incarceration
duration, based on an estimate for England and Wales.25
A recent study in Scotland reported a median sentence
of 7.1 months in PWID,27 which, given that most prison-
ers serve approximately half their sentence,28 would also
equate to a duration of 4 months.
Testing rates
The overall baseline PWID testing rate (mean 12%
undiagnosed PWID per year) was estimated through
fitting the model to the current proportion of diagnosed
PWID (approximately 50%2). Data on the proportion of
tests from each setting (29% and 12% of tests originated
from addiction services and prisons, respectively) were
used in combination with the model projected annual
numbers of PWID in contact with each setting to calcu-
late setting-specific testing rates (0.5% and 2% per
month of undiagnosed PWID in contact with addiction
services and prisons, respectively, see online
supplementary appendix). We assume that ex-PWID are
tested at equal rates to PWID in prison and in general
community settings. We assumed all diagnostic tests to
be 100% accurate due to the high sensitivity and specifi-
city of DBS (99.6% sensitivity, 100% specificity in a
setting with 50% prevalence29) and venepuncture
assays,30 and because those who receive an initial positive
test will receive additional tests before treatment.
Referral and treatment transition rates
The referral rate from testing services to secondary care
(35%) was estimated from a UK study.31 Those not
referred or not attending referral were considered to be
‘lost to follow-up’.
Approximately 50% of diagnosed ex-PWID in referral
are treated within 2 years.31–33 Since many delay treat-
ment, we assume that after 2 years, 10% of those in refer-
ral initiate treatment annually. Within prison, treatment
rates are lower than in the community,31 34 although a
recent UK prison audit found that 24% of those diag-
nosed were treated (Iain Brew(HMP Leeds), unpub-
lished data). We therefore estimated halved treatment
initiation rates in prison as compared to the community.
PWID treatment rates are unknown, but thought to be
similarly low to other countries,35 36 with an estimated
<1% of PWID treated annually (Graham Foster
(Consultant Hepatologist), personal communication).
Hence, if we assume that 1% of infected PWID are
treated within 2 years, this equates to treating approxi-
mately 5.5% of those who attend referral (35% of the
50% diagnosed) within 2 years. After 2 years, 1% of
those in referral are treated annually thereafter.
Intervention
The effect of introducing DBS was modelled by assum-
ing a 3.6-fold increase in testing (2.2 to 5.8 CI) in addic-
tion services, and a 2.6-fold increase in testing (0.1 to
34.9 CI) in prison, based on two multicentre studies
(table 1 and online supplementary appendix).
Intervention costs were determined from the study
methods5 and in consultation with the authors (table 1).
Sensitivity analyses
We performed one-way sensitivity analyses on: time
horizon (50/200 years), discount rates (3.5% costs/1.5%
QALYs), PWID treatment rates (increased in each
setting), PWID SVR rates (reduced by 20%), PWID HCV
chronic prevalence (20%/50%), antiviral treatment (tel-
aprevir/boceprevir for genotype 1 patients, see online
supplementary appendix) and continuity of care for
treatment/referral on entry/exit from prison (varied
from 0% to 100%). We also explored the effect of assum-
ing no prevention benefit (but allowing for reinfection)
by permanently fixing the force of infection.
RESULTS
Case finding in addiction services
The incremental cost effectiveness ratio (ICER) of
increasing case-finding in addiction services, by introdu-
cing DBS testing, was an estimated £14600 (US$22 630)
per QALY gained in the base case (table 2). At a
£20 000 or £30 000 WTP threshold, the intervention is
likely to be cost-effective in 69% or 93%, respectively, of
the simulations (figure 1A). Uncertainty in the interven-
tion effect contributed to 86% and 58%, respectively, of
the variation in incremental costs and QALYs. The
remaining variation in incremental QALYs was mainly
due to uncertainty in the treatment rates (22%) and
health utilities (17%).
For most sensitivity analyses, the ICER remained below
a £30 000 WTP threshold (figure 2A). Reducing the
time horizon to 50 years increased the estimated ICER
to £22 900 per QALY gained because fewer prevention
benefits were accrued, whereas lengthening to 200 years
increased the cost-effectiveness. Changing the discount
rates to 3.5% costs/1.5% QALYs or no discounting
decreased the estimated ICER to £5100 or £6700 per
QALY gained, respectively. Variations in baseline HCV
chronic prevalence had little effect (<10%). At lower
prevalence (20%), identifying cases was more expensive
but the prevention impact was greater due to the
reduced reinfection risk, whereas the opposite occurred
at higher prevalence (50%).
Increasing treatment rates increased the intervention’s
cost-effectiveness. If 50% (compared to 5.5% for base
case) of PWID in referral initiated treatment within
2 years (a treatment rate achieved by one UK service,37)
the ICER fell to £4500 per QALY gained. If SVR rates
among PWID were 20% lower than in ex-PWID, the
ICER increased by 14% (£16 700per QALY gained).
Using telaprevir/boceprevir for genotype 1 patients min-
imally altered the ICER. Ignoring any prevention benefit
doubled the ICER to £29 900 per QALY gained.
Only one sensitivity analysis substantially altered the
cost-effectiveness conclusion. If a disutility was attached
to diagnosis, the intervention resulted in negative
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incremental QALYs (due to low treatment rates) and was
dominated (more expensive with fewer health benefits).
However, even with this disutility, if treatment rates were
increased to 50% of PWID in referral initiating treat-
ment within 2 years, then the estimated ICER was
£20 100 per QALY gained.
Case finding in prison
The ICER of increasing case-finding in prison, by intro-
ducing DBS testing, was estimated at £59 400 (US
$92 070) per QALY gained (21% likely to be cost-
effective at a £30 000 WTP threshold) in the base case
(table 2 and figure 1B). Uncertainty in the intervention
effect contributed to most (>85%) of the variation in
incremental costs and QALYs.
The base-case conclusion was robust to most one-way
sensitivity analyses (figure 2B)—including time horizon,
discount rates, HCV prevalence and use of new treat-
ments. If 50% of PWID in referral initiated treatment
within 2 years, the ICER would be halved to just below
£30 000 per QALY gained.
Introducing continuity of care (which measures the
proportion of initiated treatments/referrals that are con-
tinued when entering/exiting prison) led to an increase
in cost-effectiveness: from an ICER of £59 400 per QALY
gained with 0% continuity to £10 400 per QALY gained
with 100% continuity (figure 3). The ICER fell below
£20 000 when >40% continuity of care was ensured; at
40% continuity, the intervention was 57% and 83%
likely to be cost-effective at the £20 000 and £30 000
WTP thresholds, respectively. The level of continuity
required for prison case-finding to be cost-effective also
depended on the treatment rates. If the prison treat-
ment rates were increased to equal those in the commu-
nity (50%/5.5% of ex-PWID/PWID treated within
2 years of referral), then 35% of the continuity results in
an ICER would be just below £20 000 per QALY gained.
Increasing treatment rates further so that 50% of all
referred prisoners initiate treatment within 2 years
lowers the required continuity to 20% for an ICER
below £20 000.
DISCUSSION
Main findings
Our results indicate that the introduction of dried blood
spot testing for HCV case-finding is likely to be cost-
effective under commonly used willingness-to-pay thresh-
olds in the UK (£20 000–£30 000/QALY gained12) and
the USA ($50 000/QALY gained38) in addiction services,
but not in prison, unless a minimum level of continuity
of care in treatment or referral between prison and the
community can be ensured. Ignoring the prevention
benefit doubles the ICER of the intervention in addic-
tion services. In the base case, most PWID treatments
initiated in prison were interrupted due to the lack of
continuity of care and short PWID incarceration times
(∼4 months) in the UK.25 27 Consequently, little
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prevention benefit was achieved from the prison inter-
vention, with the results approaching the ‘static’ model.
With the low base-case PWID treatment rates, the con-
tinuity required for DBS to be cost-effective was approxi-
mately 35–40% of the estimated treatment/referral
rates, but if the treatment/referral rates increased, then
lower levels of continuity would be cost-effective.
Crucially, not all treatments need to be initiated or com-
pleted in prison, as only maintaining treatment or refer-
ral contact is necessary. Finally, both interventions are
most cost-effective at higher treatment rates.
Strengths and limitations
The key strength of this analysis is that the model is
dynamic, therefore capturing the prevention impact of
case-finding and treatment. The main limitations are con-
cerned with parameter uncertainty and lack of model
heterogeneity. First, we based our increase in case-finding
on the DBS intervention which, though empirically
founded, was informed by relatively small UK studies,
resulting in wide uncertainty around the effect estimates.
Second, the base case assumed comparatively low treat-
ment rates for PWID, partly because the UK data on PWID
treatment numbers are not available. This information is
critical, as higher treatment rates increase the cost-
effectiveness. This is especially important for prisons
where treatment completion information was unavailable,
yet strongly influenced cost-effectiveness. Additionally,
even if treatment is interrupted, some may benefit from
shortened treatment, which we did not incorporate.
Third, more data are needed to quantify PWID health
utilities, which can be below the general population.39
Especially important is whether any transient or perman-
ent disutility on HCV diagnosis occurs, as current data
are weak and not based on prospective studies. Our pro-
jections indicate that if a disutility occurs, then higher
treatment rates are required for case-finding to be
cost-effective.
Figure 1 Base-case
cost-effectiveness acceptability
curves for the dried blood spot
intervention. Results shown for
the (A) addiction services and (B)
prison interventions for various
willingness-to-pay thresholds.
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Fourth, the model did not incorporate other interven-
tions or behaviours that may influence HCV risk or treat-
ment uptake. However, modelling work has shown
introducing risk heterogeneity does not substantially
reduce intervention impact if PWID circulate between
risk states,40 which is likely to occur as individuals move
in/out of drug treatment and prison.
Fifth, the model was parameterised to the UK data, so
our results are not necessarily applicable to other set-
tings. However, our conclusions are robust to changes in
HCV prevalence. Continuity of care could also be an
issue in Australia, where PWID incarceration duration is
similar to the UK.41 However, sentences are longer in
the USA,42 so fewer treatments may be interrupted, and
therefore case-finding in US prisons could be more cost-
effective than our results indicate.
Our modelled UK treatment and HCV healthcare
costs are within the range of those presented by recent
US studies,43 44 with the exception of approximately
threefold higher liver transplantation costs, which would
increase the cost-effectiveness of case-finding in the
USA. Testing costs were taken from UK economic eva-
luations; however, it is possible that a streamlined and
experienced testing service could lower costs associated
with staff time, thus increasing cost-effectiveness.
Figure 2 Univariate sensitivity
analyses on the mean
incremental cost-effectiveness
ratio (ICER). Results shown for
the dried blood spot intervention
in (A) addiction services and (B)
prison. Vertical line represents the
base-case ICER, estimated at (A)
£14 600 per QALY gained and
(B) £59 400 per QALY gained.
Figure 3 Incremental cost-effectiveness ratios for the prison
intervention with varying continuity of care assumptions.
Base-case scenario assumed 0% continuity.
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Sixth, we were unable to evaluate future interferon-free
direct-acting antiviral therapies as information on treat-
ment costs and health utilities is unavailable. These treat-
ments will most likely have increased SVR (90% for all
genotypes), shorter treatment durations (12–24 weeks),
lower toxicity and simpler dosing regimes.45 Therapies
with a shorter duration could not only increase the
impact of testing and treatment in prison as more
patients will be able to complete therapy prior to release,
but also could potentially be more cost-effective depend-
ing on the ratio of additional costs to incremental impact.
Comparison with other studies
Two publications evaluated the cost-effectiveness of
testing ex-PWID in prison, with ICERs varying from
about £20 00010 to £55 0009 per QALY gained. Our
results are consistent with Sutton et al,9 who used the
same discount rates as our study did. However, we
included the possible prevention impact of treating
PWID, and unlike the previous studies, show how con-
tinuity of care between prison and the community can
make case-finding cost-effective.
Three papers evaluated testing PWID in drug ser-
vices.10 20 46 Differences in baseline assumptions led to
varying ICERs from £28 10020 to £17 50010 46 per QALY
gained. Our results for addiction services support those
found in the latter studies.10 46 However, the interven-
tion examined in these studies10 20 46 was one-off testing
using a cohort model (with no evidence-based interven-
tion effect) and neglected any prevention benefit.
Several US studies examined birth cohort screening for
all people born in 1945–196544 47 or in 1946–197043 as
compared to risk-based screening, reporting ICERs of
$38 000 per QALY gained with direct-acting antivirals43 44
and $5 400–16 000 per QALY gained with pegIFN
+RBV.44 47 Critically, the cost-effectiveness varies substan-
tially by HCV prevalence,47 and the estimated US preva-
lence is higher than that of many other developed
countries. Additionally, ICERs were generated given
assumptions of higher treatment rates, as well as greater
utility gains with SVR than we had considered.
Importantly, our intervention targets PWID with a risk of
transmitting infection to others, whereas birth cohort
screening is likely to identify infections among
ex-injectors and non-injecting populations, which will
have little primary prevention impact.
Implications
Our cost-effectiveness work indicates that increasing HCV
case-finding in addiction services can be cost-effective.
However, the cost-effectiveness of prison case-finding inter-
ventions depends on adequate continuity of care with the
community. Few settings have developed comprehensive
strategies to address this issue, though New York recently
initiated the Hepatitis C Continuity Program.48 In all set-
tings, treatment uptake is critical: higher treatment rates
prevent more disease transmission and increase the cost-
effectiveness of case-finding interventions. If a disutility on
diagnosis occurs, higher treatment rates would be neces-
sary to ensure cost-effectiveness. Further empirical data are
required on treatment uptake and changes in utilities fol-
lowing diagnosis and treatment in order to compare tar-
geted case-finding with cohort models.
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